Search
capivasertib (Truqap)
Indications:
- combined with fulvestrant improves progression-free survival among women with ER/PR-positive, HER2-negative or low, locally advanced breast cancer
- FDA-approved for advanced breast cancer [2]
Adverse effects:
- >= 20%
- nausea, vomiting, diarrhea, stomatitis, fatigue, dermatitis,
- hypoglyemia, lymphopenia, leukopenia, neutropenia, anemia, hypertriglyceridemia, increased serum creatinine
Mechanism of action:
- AKT inhibitor
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM cid=25227436
References
- John A
Capivasterib Meets Primary Endpoint in Phase 3 Breast Cancer Trial.
Clinical Advances in Breast Cancer. Nov 14, 2022
https://www.mdalert.com/ms/cabreast/article/capivasterib-meets-primary-endpoint
- Bankhead C
First AKT Inhibitor Approved for Advanced Breast Cancer.
Capivasertib plus fulvestrant doubled progression-free survival
versus fulvestrant-placebo
MedPage Today November 17, 2023
https://www.medpagetoday.com/hematologyoncology/breastcancer/107431